Miist makes a vape-like, withdrawal-inhibitor inhaler designed to deliver medication directly to the lungs for rapid absorption. The company’s technology produces particles about 50% smaller than other inhalers, which Miist says deposits medicine deeper in the lungs for faster bloodstream uptake. Miist intentionally spaces a dose over seven puffs to mimic the behavioral ritual of smoking while providing rapid relief. A small Phase I study reported that smokers who used Miist’s inhaler eliminated 92% of their cravings in two minutes, a roughly 10x improvement over the existing standard of care according to the article. The company is preparing a Phase II trial of its smoking-cessation formulation using the active ingredient found in standard nicotine replacement therapy and is testing triptans for migraine treatment in the lab. Miist envisions expanding the platform to deliver other medicines, such as anxiety treatments, and has secured $7 million in seed funding to support development.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2025